

**Tumor Board Tuesday – Dr. Brian Rini & Dr. Joseph Vento, 03/14/2023:
Adjuvant TX RCC**

Posttest Rationale

- 1. Which of the following immunotherapies is approved for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy?**

- a. Pembrolizumab
- b. Nivolumab
- c. Atezolizumab
- d. Durvalumab

Rationale: Pembrolizumab is approved for adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy.¹ Nivolumab, Atezolizumab, and Durvalumab are not approved for this indication.^{2,3,4}

Reference: Pembrolizumab [package insert]. Whitehouse Station, NJ: Merck, Inc.; 2023.

Nivolumab [package insert]. Princeton, NJ: BMS, Inc.; 2023.

Atezolizumab [package insert]. South San Francisco, CA: Genentech, Inc.; 2022.

Durvalumab [package insert]. Wilmington, DE: AZ, Inc.; 2022.

- 2. Which of the following is a post-operative prediction model which provides a review of expected oncological outcomes in patients with RCC?**

- a. Heng Criteria
- b. Assure
- c. CAPRA Score
- d. Kattan

Rationale: Assure is used as a postoperative prediction model which provides a review of expected oncological outcomes in patients with RCC.

Reference: Correa, Andres F., et al. "Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma." *European urology* 80.1 (2021): 20-31.